Product logins

Find logins to all Clarivate products below.


Coronavirus COVID-19 Forecaster | Epidemiology | AM | 2020

The coronavirus disease 2019 (COVID-19) Epidemiology Forecaster is a fully customizable SEIR(susceptible, exposed, infectious, recovered) model that allows users to develop scenario-based global COVID-19 forecasts for up to two years from initial outbreak. Base assumptions used in this model have been tested and developed by DRG’s Epidemiology team using a semi-mechanistic methodology, running thousands of simulations with plausible parameter ranges set out by the current literature and benchmarked using daily reported COVID-19-related mortality data from the European Centre for Disease Prevention and Control (ECDC) using goodness-of-fit analysis.

Forecasting COVID-19 is challenging for several reasons, including the uncertainty in effect size and duration of local nonpharmaceutical interventions and the timing and efficacy of different treatments entering the market. Therefore, DRG’s COVID-19 Epidemiology Forecaster is flexible by design. Each variable used in the model is fully adjustable, and the tool allows the addition of up to five interventions. The COVID-19 Epidemiology Forecaster reports the following metrics in a tabular form, as well as in a variety of data visualization graphics:

  • Total case estimates (everyone infected with the virus, including laboratory-confirmed and -unconfirmed cases).
  • Mortality associated with COVID-19.
  • Adjusted infection fatality rate to allow cross-country comparisons.
  • Incident and cumulative hospitalizations.
  • Incident and cumulative intensive care unit (ICU) admissions.
  • Available in both total and age-stratified formats.

The COVID-19 Epidemiology Forecaster allows users to export diagrams and charts as image files that can easily be incorporated into internal or investor/shareholder material.

Related Market Assessment Reports

Report
Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric ADHD (US)
ADHD is a common pediatric neurodevelopmental disorder, with diagnosis rates supported by increased awareness and routine screening; however, symptoms often persist into adulthood. Longacting…
Report
Type 2 Diabetes – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth…
Report
GLP-1 receptor agonists – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth…
Report
Obesity – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth…
Report
Kidney Transplant – Current Treatment – Treatment Algorithms: Claims Data Analysis – Kidney Transplant (US)
Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent graft rejection and maintain the new kidney’s functionality, patients…